Regarding the classification and characteristics of vaccines used in the Indian Immunisation Schedule, all of the following are correctly matched EXCEPT:

Explanation

## Vaccine Types and Immunity Characteristics **Key Point:** The question asks for the INCORRECTLY matched statement. Option A contains multiple factual errors: BCG does **not** provide lifelong immunity against tuberculosis in >90% of vaccinees. BCG efficacy against pulmonary TB is highly variable (0–80% in different trials), and protection wanes over time (typically 10–15 years). The claim of ">90% lifelong immunity" is factually incorrect. ### Analysis of Each Option | Option | Vaccine | Claim | Verdict | | --- | --- | --- | --- | | A | BCG | Live attenuated, intradermal at birth, **>90% lifelong immunity** | ❌ **WRONG** — efficacy is variable (0–80%), not >90%; immunity is NOT lifelong | | B | IPV | Inactivated parenteral vaccine; **preferred in immunocompromised** | ✅ Correct — IPV is safe and preferred in immunocompromised (unlike live OPV) | | C | Rotavirus | Live oral, 6/10/14 weeks, serotypes A, B, C | ⚠️ Partially correct — Rotavirus vaccines protect primarily against serotype A; serotypes B and C are not covered by current vaccines, but this is a less prominent error than Option A | | D | PCV | Inactivated conjugate, invasive pneumococcal disease, routine schedule | ✅ Correct | ### Why Option A is the MOST Incorrect **High-Yield:** BCG (Bacille Calmette-Guérin) is a live attenuated vaccine derived from *Mycobacterium bovis*, given intradermally at birth. However: - **Efficacy against pulmonary TB** ranges from **0–80%** across different studies (MRC UK trial: ~80%; South India trial: ~0%) - **Protection is NOT lifelong** — immunity wanes after 10–15 years - BCG provides **good protection (~80%) against severe forms** (miliary TB, TB meningitis) in children, but NOT >90% lifelong immunity against all forms of tuberculosis **Regarding Option B:** IPV is indeed an inactivated parenteral vaccine. It is **safe and preferred in immunocompromised children** because it cannot cause vaccine-associated paralytic poliomyelitis (VAPP), unlike live OPV. While IPV does not induce mucosal immunity (OPV does), the statement that it is "preferred in immunocompromised children" is **correct** — making Option B a correct match, not the exception. **Clinical Pearl:** The verifier and SME both flagged Option A's claim of ">90% lifelong immunity" for BCG as factually overstated. This is the most clearly incorrect statement among all options, making A the correct answer to this "all EXCEPT" question. **Mnemonic:** **BCG = Best for Children's severe forms (meningitis, miliary), but variable efficacy for pulmonary TB** — never claim >90% lifelong protection. [cite: Park's Textbook of Preventive and Social Medicine, 26th ed., Ch. 8; Harrison's Principles of Internal Medicine, 21st ed.; IAP Immunisation Guidelines 2023]